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To xic injury to the middle and inner eal' can be cau sed by a wide range of substanc es, including therapeutic drug s, ant iseptics, and inert component s of the vehicles (table I) . Thi s artiele review s tho se systemic and topieal ototox ic agents that otola ryngo log ists encounter in everyday clinica l practice.
Nonantibiotic ototoxic drugs Chemotherapeutic drugs. Cispl atinum, vinbl astine, and vincristine are probably the most commonly used chemotherapeutic age nts. Cisplat inum is quite reliably ototoxic, but individual sensitivity varies. Some patient s experience ototox icity after j ust a single dose, while others seem to tolerate relatively high doses administered over days OI' weeks. Clini cal trials have shown that the incidenee of high-frequ ency hearing loss cau sed by the platinum group of chemotherapeutic compounds is approximately 62%.1 Th e use of sophisticated, objective meas ure ments such as otoac oustic emi ssions testin g will reveal evide nce of threshold ch anges in as many as 85 OI' 90% of pati ent s who receive a platinum agent. ' The high-frequency hearing loss experienced by these patients is usually permanent , but it is not asso ciated with any sig nifica nt vestibulal' ototox icity.
Loop diuretics. Ototoxicity caused by the loop diuretics, pri marily furose mide and ethacrynic acid, is usuall y seen in patients with renal failure and in tho se who receive relatively high doses. For example, furosemide ototox icity is usually see n in patient s who receive 200 to 500 mg in a matter of seve ral hou rs. Loop -diuretic-induced ototoxicit y is marke d by edema of the stria vascularis and changes in ionic potentials in the endolymph and peri-Iymph. In expe rimental anima Is, strial edema correl ates rather nicel y with the amount of threshold shift. Fortunately, the strial ede ma is a tran sient condition, and ototoxicity caused by a loop diuretic is generally reversible.
Salicylates. The first known report of the therapeutic value of willow bark dates from the 4th century B.C. Americans currently take an estimated 10,000 to 20,000 tons of salicylates annually. The reported incidenee of ototoxicity caused by salicy lates is as high as 11 per 1,000 pati ent s.? Salicylate ototoxicity also occurs in patients who take relative ly high doses. Ototoxicity manifests as a 10-to 20-dB flat sensorin eural hearing loss that resolv es 24 to 72 hour s after the agent is discontinued.
NSAIDs. The nonsteroidal anti-infla mmatory drug s (NSAIDs) are similar to the salicylates, but the incidenee of ototo xicity with NSAIDs is much lower. However , unIike the salicylates, the NSAIDs have been noted in some credible case reports to cause irrev ersible sensorineura l hearing loss.
Quinine. Quinine ototoxicit y is often grouped together with salicy late otot oxicit y, but they are quite different in that the form er manife sts not as a flat hearing loss but rath er as a high-frequ ency sensorineural hearin g loss. Moreov er, quinine toxicity is associ ated with some meaningful vestibul ar toxicity, which is not generally see n in salicylate ototoxicity. Quinine-induced vestibular toxicity can be reversed with prompt reco gnition and treatment, but long-standin g toxicity is frequently irreversible.
Initially, quinine-induced ototox icity was seen prim arily in patients with malaria, which is not now amajor probl em in the United States. However, quinine is bein g incr easingly prescribed by primary care physicians for the treatment of leg cramps, and there are some reports of significa nt vestibul ar dysfuncti on as a res ult. Becau se of quinine' s effect on the vestibul ar system, the military now prohibits pilot s from flying their plane s within 48 hours of takin g the agent.
Systemic antibiotic ototoxicity
The two elasses of antibiotics known to cau se ototo xicity are the macrol ides and the aminog lycos ides. Vancomycin is usuall y inelud ed on lists of ototox ic antibiotics , but such a designation is difficult to justify . Very few case reports of purp orted vanco mycin-induced oto toxicity are co mpelling . One reason for this is that the affected pa-Volume 82 • Suppl 1 ·3 tients had often been taking an aminoglycoside either concomitantly with, or shortly before, they started vancomycin . Moreover, other potential causes of ototoxicity were noted in these patients. Therefore, although vancomycin is widely believed to be ototoxic, the evidence to support that claim is weak .
Macrolides. Erythromycin-induced hearing loss has bee n wel1 recognized for a long time, but its mechanism is not wel1 understood. Erythromycin ototoxicity is gen-eral1y reversible; of the 30 or 40 case reports I reviewed, I fou nd only two or three in whic h hearing loss was permanent.
Reports of ototoxici ty with azithromyci n and clari thromycin are less com mon, but the pereentage of cases that involved permanent hearing loss is probably higher. For the most part, azithro mycin ototoxicity and clar ithromycin ototoxicity have been seen in patients who received relatively large intrave nous doses for the treatment of fairly serious diseases. Reports of ototoxicity fol1owing oral admin istration of either drug are relatively uncommonuniike the case with erythromycin, where many of the cases of ototoxicity are related to oral use.
A tninoglycosides. The aminoglycosides can be both cochleotoxic and vestibulotoxic. Development of these drugs began in the 1940s as part of a rigorous and systematic attempt to evaluate microorgan isms , partic ularly fungal organisms, for their potential to create antibiotic substances.
The first aminoglycoside was streptomycin, which was crea ted from the fungus-like bacterium Streptomyces griseus. Streptomyein's ototoxie potential was reeognized quite early. In response, researehers modified the drug's moleeule and created dihydrostreptomyein. Unlike its predeeessor, dihydrostreptomyein is mueh more eoe hleotoxie than it is vest ibulotox ie; in fact , it is almost exaetly as eoehleotoxie as streptomyein is vestib ulotoxie . Later, investigators tried to reduee the risk ofboth toxieities by eombi ning equal amounts of the two drugs , but this only resulted in patients experieneing both toxieities rather than neither.
Systemic aminoglycoside ototoxicity
In 1990, Govaerts et al published a study in whieh they eompared the ototoxie potential of various aminoglyeosides in animals.' They found that gentamiein, kanarnyein, and tobramycin were equally eoehleotoxie, and al1 three were more eoehleotoxie than amikaein. In terms of vestibular ototoxieity, they reported that streptomyein was more toxie than gentamiein, whieh was more toxie than tobramyein. They did not study neornycin, beeause it is so reliably eoeh leotoxie that it was never approved in the United States for systemie use.
Inciden ee. Many authors have reported that the incidenee of ototoxicity among patients who take a systemie aminoglycoside is only 2 to 3%. However, Govaerts et al found mueh higher rates .' They reported that the incidenee of eoehlear and vestibular toxieity with gentamiein was approximately 8 and 14%, respee tively. Th e eorrespo nding rates with amikae in were 5 and 13%, and the rates with tobramyein were 14 and 3%, respeetively. It is interesting that the incidenee of vesti bular toxieity with amikae in was nearly as high as that of gentamiein. The incidenee is even higher when objeetive testing is used to deteet ototox ieity. For example, over the eourse of any antibiotie regimen, the incidenee of threshold shift is approximately 50% when ultrahigh-frequeney audiometry is perforrned.' Most of this toxieity manifests in the range of 9 to 15 kHz, a range that is not eval uated dur ing routi ne clinieal testingoIn additio n, studies of rotatio nalehair testing in asym pto matie patients on aminoglyeoside therapy have found that as manyas 39% of patients experience statistieally signifieant ehanges in gain.' Findings on objee tive testi ng correlate reaso nably weil with anima l pathology .
Cochlearpatho logy, The pathology of aminoglyeoside ototoxie ity invo lves injury to the orga n of Corti. Such an inj ury is always worse in the basa l turn of the eoe hlea than at any other site. In experimental animals, the starting point of degeneration is very clear-eut: 6 to 8 mm from the rou nd window in the basal turn. The damage then spreads rapidly to the round window and more slowly toward the apex of the eoeh lea. The degeneration proeee ds prog ressively and involves higher and higher freq ueneies.
The outer hair eelis are mue h more suseeptible to injury than are the inner hair cells.? Among the outer hair eelis, those in the inne r row are the most suseeptible; those in the middle row are less suseeptible, and those in the outer row are the least suseepti ble (figure I). In more severe cases, damage progresses to the inner hair eelis and ea n eve n spread to the supporting eelis in this order: Deiters' eelis, pillar eelis, and Claudius' eelis. Aeeord ing to Lim, histopathologie findings on light mieroseopy in ami noglyeoside-indueed eoehleotoxiei ty are quite simi lar to those seen in noise-indueed hearing IOSS.7 Vestibularpathology. In terms of vesti bular pathology, the erista amp ullaris of the sem ieireular eana l is more vulnerable than the maeu la utrieuli , whieh is more vulnerable than the mae ula saccu li." Type I hair eelis are more susee ptible than type II hair eelis .
Pharmacokin etics. For several deea des it was thought that aminog lyeosides eoneentrated in inner-ear fIuidspartieul arly perilymph-to a greater degree than they did in seru m. Researehers believe d that the serum aminoglyeoside eoneentration peaked within 1 hour of IV administration and then bega n to decli ne. Perilymph eoneen trat ions, on the other hand, were thought to inerease for as long as 12 hours. Simi larly, the kineties of arninoglyeosi de removal were believed to be just as slow. New studies, however, have posed a eompelling ehallenge to these theories. It now appears that aminoglyeosides do not eo neen trate at all in inner-ear fIuids. Ami noglyeos ides do eo neentrate in port ions of the hair eelis and the organ of Co rti.
Me cha nis m of action. The aminoglyeosi des' meehanism of action at the moleeu lar level remai ns unknown. Co mpliea ted theories surface every 4 or 5 years, but none has been defi nitively proven. The mos t eurrent popul ar theory is that the aminoglyeoside itse lf is not toxie; rather it is a metabolite of the aminoglyeoside that eauses ototoxici ty." Some evidenee has been gathered that the formation of an iron-aminoglyeoside eo mplex generates free radieals.
R isk factors. The mos t important risk fae tors for aminoglyeoside ototoxieity are renal insuffieieney, the eoneo mita nt use of other drugs (espee ially other ami noglyeosi des and loop diureties and, less frequently, the ehemotherapeutie agen ts), and the patient's age. ' Researehers have also diseovered that a subpopulatio n of patients has an alteration in the 12S subunit of their mitoe hondrial DNA (an adenine-to-guani ne shift at pos ition 1555) that makes them suseeptible to aminog lyeosi de Volume 82 • Suppl 1 • 5
OtOtOX IClty. Fischel-Ghods ian et al reported that this mutation was found in seven of 41 patients ( 17. 1%) who had aminogly cos ide ototox icity, com pared with none of 400 co ntrois who did not.?Patient s with this mutation can experience significant hearing loss after onlyone or two doses.
Fam ily history can be key to identi fying these at-risk patient s. In the study by Fischel-Ghodsian et al, several patient s reported that two or three famil y memb ers had previ ously experie nced significa nt aminog lycos ide oto-toxicityYHoweve r, this particul ar mutation certainly does not acco unt for all cases of ototoxicity; other ge netic defect s might also be responsible. In fact, the degree of individual variability and susce ptibility strongly argues that multipl e genetic features co ntro l the emergen ce of aminog lycoside ototoxicit y.
Dosage. Numerous studies have show n that there is no "safe" dose-that is, no amo unt of medi cation and no numb er of doses that ensure that ototox icity will not occ ur. Aga in, ototox icity can occ ur after just a single dose. Therapeut ic peak and trough levels do not guara ntee that oto tox icity will not occ ur. Halm agyi et al repor ted a series of36 patients with ototoxicity and found that fewe r tha n half had elevated peak levels, fewer than half had eleva ted trough levels, and two of the 36 had elevations in both peak and trough levels." Most of the patien ts they evaluated had neve r exceeded the "safe" dosage of 5 mg/ kg/day, and almost none had exceeded the total dose of50 mg/kg, also considered "safe." It appears that patients who have both rece ive d a high total dose and undergone prolonged treatment are at higher risk for ototoxicity, but either one of these factors alone does not seem to increase the risk.
Symptoms. Hearing loss and tinnitu s are the symptoms of cochle ar injury. Th e princip al hallm ark of vestibular injury is gait ataxia that becomes worse when the patient is in darkne ss or is wa lking on a soft or uneven surface. Th ese symptoms are not man ifest in a patient who is very iil or bedridden . Dizzin ess or vert igo is rare in vesti bular ototox icity; in the series by Halmagyi et al, none of the 36 patient s co mplained of rota tiona l vertigo of any type. ID Sign s. The primary sign of coc hlear injury is a decrease in hearing thres hold on audio metry , stapedius reflex testing, or otoacoustic emissions testi ng. Otoacoustic emissions testing can be a reasonable method of monitoring these patients dur ing the course of therapy. Signs of ves tibular dysfunction incl ude a positive Rornberg' s test, a decrease in visual ac uity on head shak ing, the emerge nce of com pensatory saccades on passive head shaking, and vertica l osc illo psia in darkness or on an uneven surface . These signs ca n be detected at the bedside.
Monitoring. Rigorous maintenance of peak and trough levels is no guarantee that a patient will not experie nce ototoxicity. Unfortunately, the threat of medico lega l con-seq uences co mpels the physician to maintain them anyway . We are force d to practice defensive medici ne eve n though it is notnecessarily going to help the patient. I have studie d a number of cases as a pote ntial expert wit ness . If a lawyer can find that measurement of eve n one peak or trou gh level was made, say, 42 minutes after the last dose of am inoglycoside rather than 30 minutes, he can arg ue that the physician violated hospital policyand is, therefore, in legal jeopardy. Thi s is a perplexi ng problem.
On the other hand , we do know that an eleva ted serum crea tinine level is corre lated with an increase d risk of ototoxicit y. Th erefore, it is in the best interest of both pati ent s and physicians to closely monit or renal function . Alarm bells should go off if the serum creatinine level begin s to rise.
Physicians might consider other types of objective monitoring for coc hlear and vestibular function. For coch lear function, physicians should take serio usly co mplaints of tinnitus fro m patient s who are taking an aminog lycosi de, and test them. From a stric tly techn ical point of view, the physic ian would idea lly obtain an audiog ram, preferabl y a high-frequency audiogram. Of course, this is not a realis tic option in a hospital sett ing. Another option is to obtai n bedside meas ure ments of the stapedius reflex and otoacoustic emissio ns. Hand-held otoacoustic emissions testi ng devices are avai lable. As a practical matter, however, I am not aware of any physician who actually does this, and I am not necessarily reco mmending it.
Several methods are effective in objective ly monit oring ves tibular function. Rotational-chair testin g is the most sensitive and repr odu cibl e means of eva luating bilateral vestibular hypofunction. Caloric testin g can also be helpful, although dysfun ction does not becom e app arent until there is a 20 to 30% change in saccadic velocity. Vestibular autorotation testin g can be useful , although it is ex pensive and difficult to perform. Agai n, none of these tests is practical for eva luating a very iil patient. Oth er possi bilities for patient s who are weil enough to undergo bedside testing include the head-thru st rnaneu ver, eval uation for post-head-shake nystagmu s, or testin g to deteet dynamic changes in vis ual acuity. Another possibil ity is a Rom berg ' s test.
Management. Before initiating systemic aminoglycoside therapy, it is imperative to obtai n informed co nsent. The physician must make the patient completely aware of the risks and doc ument having do ne so. The absence of informed consent is a freque nt point of co ntention in med icolegal cases. AIso, discontinue aminoglycoside therapy as soo n as ototox icity is ide ntified or suspecte dass uming that this is possible without enda ngering the patient ' s health in some othe r way . Steroi d therapy might be useful, as will be discusse d later. Finally, vestibular rehabilitation is very helpful for patients who have experienced significant vestibular inju ry. In this study, several topieal medieations-earbenieillin, eoli stin , nystatin, and penieillin G-showed no evidenee of toxieit y or irritation, but these are age nts that otolaryn gologist s do not use very often . Distilled wate r and 0.9% sodium ehloride also eaused no middle ear toxieity . Only moderate middl e ear tox ieity was seen with topieal gentamiein, whieh is in eontrast to the severity of inner ear ototo xieity that ean be seen. Mode rate toxi city was also seen with baeitraein, ehlo rhexidine, and tetra eyeline. Severe middle ear toxieity was seen with topie al amphoteriein B, ben zalkonium ehloride, and ehloramphenieol and with two common vehiele preparations, polyeth ylene glyeol and propylene glyeol. Park er and Jam es eoneluded that beeause the middl e ear mueo sa is so suseeptible to irritation and subsequent hyperpl asia, eardrops that contain polyethylene glyeol and propylene glyeol should be avoided beeau se they ean damage the eili a."
At my institut ion-the Universit y of Tex as Southwestern Medical Center in Dallas-we looked at a number of these medieations in our labor atory animals." One of our findings was that although a single dose of the eombination agent sulfaeetamide/prednisolone was not toxie to the inner ear, it was fairly irritating to the middle ear (figure 2). One week after admini stration , this agent had eaused a marked inflammation of the mueosa in addition to oecasional hemorrhaging and serous effusion . We also saw hem orrhage and hyperplasia of both the lateral and medial surfaees of the tympani e membrane. Four weeks after administration, these ehan ges had substantially resolved.
Anoth er eombination agent that was quite harmful to the middle ear was polymyxin/neomyein/hydrocorti sone (PNH), possibly beeause it is delivered in propylene glyeol. Adm inistrat ion of this agent led to the format ion of mild to severe granulation tissue, and it eaused effu sion , foeal hemo rrha ge, and osteoneo gene sis. Inner ear ototoxicity from topieal agents Variaus vehieles, anti sept ics, antifungals, and antibiotics have been studied in an attempt to determine if they are toxic to the inner eal' whe n administered topi cally:
Vehicles . Polyethylene glycol and propylene glycol have shown some evidence of inner eal' toxicity , as has ben zalkonium chloride.
Antiseptics. Acetic acid, alcohol , ch lorhexidine, Cre sylate, and genti an violet all have ototoxic potential. Chlorhexidine is quite ototoxic (as Dr. Rutka addresses in more detail in his artiele beginning on page 9). Gentian violet is so ototoxic that in one study, researchers who had intended to dose 10 animals with it eventually dosed only four , becau se three of the animals became so iil from vestibular toxicity. Acet ic acid's ototoxic potential is worri sorne. " Alcohol is not nearly as ototoxic as the other antise ptics. The only antiseptic that has been shown not to be ototoxic is povidone iodin e. "
Antifungals. Anti fungal s are almost uniformly nontoxic to the inner eal'.Clotrimazole , micon azole , nystatin, and tolnaft ate have all been investigated for cochl ear OI' vestibular toxicity, and none has been found . A number of publi shed studies and severa l experts in infectious disease have found that elotrimazole is probably the most effective in eradicating Candida and Asperg illus spec ies. Tom reported that nystatin was not toxic to the inner eal', but it left a thick residue in the middl e eal'space that might lead to toxicity of the middle ear. "
Antibiotics. Among the topieal prep arations that are severely toxic to the inner eal'are polymyxin B, chloramphen icol , ticarcillin/elavulanate, and all of the arninoglycoside-containing agents. At my institution, we found that polymyxin B was actually more toxi c than even neornycin .
A single D.S-ml dose of PNH into the eal' of an experiment al animal will destroy the organ of Corti. " Approximately 3 weeks after admi nistration, it will cause a loss of myelinated nerve fibers in the lamin a spiralis ossea ; after 3 month s, onlyabout one-third of these fibers rem ain. PNH also causes a loss ofhaircell s in the erista ampull aris, the macula utriculi , and the macula sacculi, and a marked degeneration of the stria vasculari s.
Antibiotics that are not ototoxic inelude the fluoroquinolones (ciprofloxacin and ofloxacin), cefta zidime, and sulfacetamide. Prior to the quinol one era, our labora- tory studied cefta zidime with the idea offormulating it as an otic drop. However, ceftazidime has since been surpassed in bacteriologic efficiency by the quinolones.
Prevention of ototoxicity
A number of agents have been shown to protect against ototoxicity (table 2) . Combining fosfomycin with an aminoglycoside has been repeatedly shown to proteet from ototoxic ity, although the reason it does so is unele ar. AIso, a small amount of fosfomycin has been shown to completely proteet guinea pigs from the ototo xicit y associated with PNH. Caleium is another antagonist to aminoglycoside ototoxicity when it is delivered rapidly at the appropriate time . Alpha lipoic acid, antioxidants, and iron chelators have also been shown to be protective in animal model s, and this is one basis for the curr ent theory that an iron-amino glyco side mol ecule might be responsible for ototoxicity by creati ng free radicals.":"
